2 active not recruiting, 1 completed, 1 recruiting. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Completed 1 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Lung Non-Small Cell Squamous Carcinoma: new trials by email Literature Review of Lung Non-Small Cell Squamous Carcinoma trials Research Report on Lung Non-Small Cell Squamous Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer Berzosertib, Biospecimen Collection, Carboplatin - Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 12 | 2021-04-14 | 2026-09-21 |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) Biospecimen Collection, Carboplatin, Cisplatin - Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 1210 | 2020-06-16 | 2026-10-30 |
| Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Rucaparib - Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation | Phase 2 | Completed | SWOG Cancer Research Network | 64 | 2019-04-16 | 2025-05-21 |
| Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer Nivolumab, Stereotactic Body Radiation Therapy - Lung Atypical Carcinoid Tumor, Lung Neuroendocrine Neoplasm | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 140 | 2017-06-26 | 2026-06-22 |
Lung Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Adenocarcinoma of Lung (2) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Carcinoma, Neuroendocrine (1)
Lung Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Adenocarcinoma (2) · Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Nerve Tissue (1) · Neuroectodermal Tumors (1)
Carboplatin (2) · Gemcitabine (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · pembrolizumab (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Cisplatin (1) · Nivolumab (1) · Observation (1) · Paclitaxel (1) · Pemetrexed (1) · Platinum (1) · Radiosurgery (1) · Taxes (1) · berzosertib (1)
National Cancer Institute (NCI) (2) · M.D. Anderson Cancer Center (1) · SWOG Cancer Research Network (1)
United States (4) · Guam (1)
Jacob M Sands (1) · Joe Y Chang (1) · Jonathan W Riess (1) · Liza C Villaruz (1)
PMID 33878954, PMID 37478883, PMID 41206673, PMID 41747891, PMID 41911908, PMID 42335416
U10CA180821 (1), U10CA180888 (1), UM1CA186690 (1)